Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform
Authors' conclusion
Patients with CKD and T2D who initiated finerenone experienced a substantial reduction in UACR, a slight decrease in eGFR, and were generally well tolerated during follow-up. These findings reinforce the effectiveness and safety of finerenone in Chinese real-world clinical practice.
Study context
- Population
- Adult patients with chronic kidney disease (CKD) and T2D who initiated finerenone between January 2023 and December 2024, Tianjin, China; 66.4% male; mean age 57.6 yearspatients included
- Participants
- 6,537 patients
- Outcome
- Median UACR change
- Follow-up
- Month 4
Methodological detailselectronic health records
- Electronic health records
Main finding
As reported in the abstract
Median urinary albumin-to-creatinine ratio (UACR) decreased substantially by
40.7% (95% confidence interval [CI]: 32.2%, 49.1%)
Observational data: associations, not effects.
Further findings
Mean estimated glomerular filtration rate (eGFR) change · Month 4
- Mean eGFR declined slightly by
- 3.2% (95% CI: 2.4%, 4.0%)
Mean serum potassium change · Month 4
- Mean serum potassium increased by
- 4.6% (95% CI: 3.9%, 5.3%)
KDIGO risk categories at baseline
- Of patients with baseline UACR and eGFR values, categorized as moderate, high, or very high KDIGO risk
- 97.0%
Subgroups
- These trends were generally consistent across subgroups
Safety
Hyperkalaemia events · follow-up
- Incidence rate of hyperkalaemia events
- 4.1 per 100 person-years
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →